Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...

CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...

Diving into Analyst Ratings: An In-Depth Exploration The standing of BioNTech among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below ...

U.S.-listed shares of BioNTech fell Monday, as the COVID-19 vaccine maker’s soft sales outlook offset better-than-expected quarterly results. The German company said it expects 2025 total ...

March 10 (Reuters) - German COVID-19 vaccine maker BioNTech (22UAy.DE), opens new tab on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ($1.85 billion ...

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to co-develop the prospect, BioNTech let the option expire as part of its ...

While BioNTech has evolved significantly since its ... The majority of these responses were poly epitopic directed against multiple mRNA-encoded neoantigens, and these responses were de novo ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging ... invention of CureVac, called split poly-A tail technology, which enhances medical efficacy ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 ...